Xeris Biopharma (NASDAQ:XERS) Sets New 1-Year High on Analyst Upgrade

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)’s share price hit a new 52-week high during mid-day trading on Wednesday after Barclays raised their price target on the stock from $14.00 to $18.00. Barclays currently has an overweight rating on the stock. Xeris Biopharma traded as high as $16.35 and last traded at $16.2060, with a volume of 277,899 shares changing hands. The stock had previously closed at $15.83.

XERS has been the topic of several other research reports. HC Wainwright increased their target price on Xeris Biopharma from $10.00 to $18.00 and gave the stock a “buy” rating in a research report on Friday, November 6th. Piper Sandler reiterated a “neutral” rating and issued a $12.00 price target (up from $8.00) on shares of Xeris Biopharma in a research report on Friday, November 6th. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research note on Wednesday, November 4th. Finally, Leerink Partners increased their price objective on Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a report on Thursday, September 10th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $17.00.

Insider Activity

In related news, insider Steven Pieper sold 5,000 shares of the business’s stock in a transaction that occurred on Monday, November 2nd. The shares were sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the transaction, the insider owned 1,346,053 shares of the company’s stock, valued at approximately $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Beth Hecht sold 25,000 shares of the company’s stock in a transaction that occurred on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $255,750.00. Following the sale, the insider directly owned 1,086,130 shares in the company, valued at $11,111,109.90. This trade represents a 2.25% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last ninety days, insiders sold 168,332 shares of company stock worth $1,678,971. 4.35% of the stock is owned by company insiders.

Top Xeris Biopharma Stories

Here are a few of the latest stories about XERS:

• Positive Sentiment: HC Wainwright reiterated its “Buy” rating and $18 price target while raising its earnings forecasts: FY2026 EPS to $0.14 from $0.04, FY2027 to $0.13 from $0.11, and FY2030 to $1.03 from $0.92. The higher longer-term outlook suggests improved expectations for earnings growth. Xeris Biopharma coverage
• Positive Sentiment: Wall Street Zen upgraded Xeris, and a separate brokerage roundup characterized the stock’s consensus rating as “Moderate Buy.” These ratings add to the favorable analyst tone. Wall Street Zen upgrade Brokerage ratings
• Neutral Sentiment: The short-interest item calls the change a “large increase” but reports zero shares short as of November 10. Because those details conflict, it offers no clear signal about short-selling pressure or potential short covering.

Institutional Investors Weigh In On Xeris Biopharma

A number of institutional investors and hedge funds have recently made changes to their positions in XERS. Ieq Capital LLC boosted its position in shares of Xeris Biopharma by 26.0% during the 3rd quarter. Ieq Capital LLC now owns 124,012 shares of the company’s stock valued at $1,186,000 after acquiring an additional 25,583 shares during the last quarter. Royce & Associates LP grew its holdings in shares of Xeris Biopharma by 27.5% during the third quarter. Royce & Associates LP now owns 588,178 shares of the company’s stock worth $5,623,000 after purchasing an additional 127,025 shares in the last quarter. Knights of Columbus Asset Advisors LLC purchased a new position in shares of Xeris Biopharma during the third quarter worth about $1,275,000. StoneX Group Inc. bought a new position in shares of Xeris Biopharma in the third quarter worth approximately $142,000. Finally, Pictet Asset Management Holding SA increased its position in shares of Xeris Biopharma by 13.7% in the third quarter. Pictet Asset Management Holding SA now owns 34,107 shares of the company’s stock worth $326,000 after purchasing an additional 4,108 shares during the last quarter. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Xeris Biopharma Stock Performance

The company’s 50-day moving average is $9.92 and its two-hundred day moving average is $7.70. The company has a market capitalization of $2.95 billion, a P/E ratio of -321.80 and a beta of 0.61. The company has a quick ratio of 1.02, a current ratio of 2.15 and a debt-to-equity ratio of 3.89.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, November 5th. The company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.03 by $0.03. Xeris Biopharma had a negative net margin of 1.76% and a positive return on equity of 147.75%. The business had revenue of $107.23 million during the quarter, compared to analyst estimates of $101.68 million. Equities analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

About Xeris Biopharma

Xeris Biopharma is a commercial-stage biopharmaceutical company focused on developing and providing treatments for people with endocrine and other serious health conditions. Its products include Gvoke, a ready-to-use glucagon product for the treatment of severe hypoglycemia, and Recorlev, a treatment for adults with endogenous hypercortisolemia associated with Cushing syndrome when surgery is not an option or has not been curative. The company also develops drug-delivery technologies intended to make medicines easier to store and administer.